Bladder cancer can cause pain when it spreads to different areas of the body. From NSAIDs to nerve blocks, here are the ...

Ferring Pharmaceuticals announces that nadofaragene firadenovec-vncg (ADSTILADRIN ®) has been upgraded to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for the ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder cancer with papillary only disease. This update extends recognized use of ...

The American Cancer Society estimates that over 55,000 people will die from colorectal cancer in the U.S. this year. Of those, 7% will be under 50.

Large international study finds nearly half of patients admitted with visible blood in urine receive no imaging, delaying ...